ISG15 and neoplasm: ISG15 and PD-L1 form ISGylation which involving k-48 ubiquitin-chain and then destabilizes glycosylated PD-L1 and promotes its degradation through the ubiquitin–proteasome pathway, thus activating anti-tumor immune function.